FDA Inspection 1218002 — BioGenetics Corporation
The FDA completed an inspection of BioGenetics Corporation on Sep 5, 2023 in Mountainside, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 5, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Mountainside, NJ (United States)